Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and Long-term Safety of Oral Semaglutide Versus Sitagliptin in Subjects With Type 2 Diabetes

Trial Profile

Efficacy and Long-term Safety of Oral Semaglutide Versus Sitagliptin in Subjects With Type 2 Diabetes

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 05 Jun 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Semaglutide (Primary) ; Metformin; Sitagliptin
  • Indications Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms PIONEER 3
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 31 May 2023 Results of a post-hoc analysis from clinical trials: PIONEER 1-5 and 8 assessing clinically relevant composite endpoints of HbA1c (glyclated haemogloblin) reduction published in the Diabetes Therapy
    • 23 Sep 2022 Results of an exploratory analysis assessing time spent by patients with HbA1c <7.0% (53 mmol/mol), and likelihood of maintaining this glycaemic control using data from four clinical studies: PIONEER-2, PIONEER-3, PIONEER-4 and PIONEER-7 presented at the 58th Annual Meeting of the European Association for the Study of Diabetes.
    • 12 May 2022 Results evaluating Cost-Effectiveness of Oral Semaglutide in Spain by deriving data from PIONEER 2, PIONEER 3 and PIONEER 4, published in the Advances in Therapy
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top